BioNTech

(IN BRIEF) The European Investment Bank and European Commission are jointly supporting BioNTech’s mRNA manufacturing facility in Kigali, Rwanda, with up to €95 million in blended financing. The project aims to strengthen Africa’s capacity to produce vaccines locally for diseases … Read the full press release →

Europe’s RNA immunotherapy sector is gaining speed with new in vivo CAR-T and mRNA vaccine trials. Germany approved the region’s first in vivo CAR-T study, marking regulatory progress. The UK’s Cancer Vaccine Launch Pad advances personalised mRNA cancer vaccine trials … Read the full press release →

(IN BRIEF) Pfizer and BioNTech have received a positive recommendation from the EMA’s CHMP for their LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY® LP.8.1, for individuals aged six months and older. This updated vaccine offers improved immune protection against prevalent SARS-CoV-2 subvariants, … Read the full press release →

(IN BRIEF) BioNTech agreed to buy CureVac in an all-stock deal valuing CureVac at ~$1.25 billion, exchanging each share for $5.46 in BioNTech ADSs—a 55% premium to its recent stock price. The merger, expected to close in 2025, strengthens BioNTech’s … Read the full press release →